Orsay, France, May 27th, 2024, Blue Bees Therapeutics, a biopharmaceutical company specialized in
the development of first-in-class immunotherapy to treat cancer, announces today:
- The appointment of Dr Marie-Noëlle Ly as Chief Development Officer (CDO) in charge of the
regulatory preclinical development of the Company’s products up to the first-in-human trials.
Marie-Noëlle also joins the Company’s executive committee. - The appointment of Mr Thomas-Paul Descamps as independent non-executive director to join
the company’s board of directors.
